Expert Interview
Digging into ImmunoGen’s ELAHERE (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer following FDA Accelerated Approval Decision
Ticker(s): IMGNAn oncologist with experience in treating Platinum-Resistant Ovarian Cancer.
Please describe your practice as a clinician,how many patients with Platinum-Resistant Ovarian Cancer do you treat on a yearly basis? Could you walk us through the standard of care, and tell us a bit about the most promising upcoming treatments, or interesting clinical trials in this space?
How much of an unmet need is there in the field of PROC? How much use do you see for ELAHERE, going forward?
ImmunoGen has to clear the confirmatory Phase 3 (MIRASOL) trial to gain full approval, could you please analyze the trial for us and give us the main takeaways?
The approval is based on the SORAYA trial in 106 patients, with 31.7% Objective Response Rate and 6.9 months Duration of Response. Could you please discuss the findings of this trial, and how it compares to standard of care?
Added By: slingshot_insightsElahere will be used in conjunction with a companion diagnostic known as VENTANA FOLR1 RxDx Assay that is approved with the drug. How likely is it to become another layer of complexity in deterring prescription?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
